Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc.NCT06106672
Phase 4
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod: A Single Arm, Open Label Prospective Cohort Study
This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG). E…
Myasthenia Gravis CrisisMyasthenia Gravis ExacerbationsAChR Myasthenia Gravis
University of Colorado, DenverNCT06860633